

16 September 2013 EMA/HMPC/566094/2013 Committee on Herbal Medicinal Products (HMPC)

Committee on Herbal Medicinal Products (HMPC)

Draft Agenda of the 16-17 September 2013 meeting

Chair: Werner Knöss

16 September 2013, 14:00 – 19:00, room <u>4A</u>

17 September 2013, 8:30 - 12:00, room <u>4A</u>

Health & Safety Information

In accordance with Agency policy, delegates are to be shown a slide show with health and safety and emergency information and procedures. This is to be displayed at the start of this meeting using the Crestron system as delegates are entering the meeting room. In addition, the meeting secretariat is to draw the delegates' attention to the slideshow and point out the nearest fire exit(s), which are marked where the room has two or more exits. Should there be an evacuation during the meeting staff will guide delegates out of the building via the nearest fire exit.

• Announcement of new nominations, changes to composition

Tina Engraff, European Commission representative at HMPC (Unit D-6)

Declaration of conflict of interests

In accordance with the Agency's Policy and Procedure on the handling of conflicts of interests, participants in this meeting are asked to declare any conflict of interests on the matters for discussion (in particular any changes, omissions or errors to the already declared interests). Discussions, deliberations and voting will take place in full respect of the restricted involvement of Scientific Committee members and, where relevant, experts attending the plenary meeting, as announced by the Scientific Committee secretariat at the start of the meeting.

- Draft annex to the minutes for the September 2013 HMPC meeting, documenting anticipated restriction on involvement in relation to agenda topics and declarations of interest from members and alternates (EMA/564107/2013)

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom **Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7455 **E-mail** info@ema.europa.eu **Website** www.ema.europa.eu



An agency of the European Union

© European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged.

I. Introduction	 * = Change introduced following last pre-meeting mailing
I.1 Agenda, minutes	
I.1.1 Agenda of 16-17 September 2013 HMPC meeting (EMA/HMPC/566094/2013): for adoption	To be tabled at meeting
I.1.2 Time schedule of 16-17 September 2013 HMPC meeting (EMA/HMPC/538032/2013 Vers.1): for adoption	To be tabled at meeting
I.1.3 Draft minutes of 8-9 July 2013 HMPC meeting	Circulated on 5 August 2013
(EMA/HMPC/453569/2013): for adoption	Premail 2 – 10 September 2013
I.2 Legislation and regulatory affairs	
I.3 Questions raised by HMPC members	
I.3.1 Question by R. Länger dated 12 August 2013 in relation	Report by R. Länger
to estragole amounts in herbal extracts and average intake of estragole by food: for discussion	Premail 1 – 2 September 2013
- Email	
- *Public statement on the use of herbal medicinal products containing estragole (EMEA/HMPC/137212/2005)	<u>http://www.ema.europa.eu/docs/en_GB</u> /document_library/Scientific_guideline/2 010/04/WC500089960.pdf
I.4 Questions raised by companies	
I.4.1 Registration of combination herbal medicinal products in relation to the marketing authorisations for medicinal products	Report by /HMPC Chair In the presence of T. Engraff (Eur Com) In the presence of
I.4.1.1 Letter from dated 22 July 2013	Premail 1 – 2 September 2013
I.4.1.2 Draft response letter to dated 16 September 2013 (EMA/560660/2013): for adoption	To be tabled at meeting
I.5 Referral procedures	
II. Co-ordination issues	
II.1 General co-ordination issues	
II.2 Co-ordination with CHMP	
II.3 Co-ordination with SAWP	

II.4 Co-ordination with SWP	
II.4.1 SWP comments on draft public statement on the use	Rapporteurs: J. Wiesner/O. Pelkonen
of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs) (EMA/HMPC/893108/2011): for discussion	Outcome written procedure at SWP
II.4.1.1 Public statement (EMA/HMPC/893108/2011)	Premail 2 – 10 September 2013
II.4.1.1.1 Overview of comments (EMA/HMPC/280542/2013) Premail 2 – 10 September 2013
II.4.1.2 SWP comments dated 22 July and 1 August 2013	Premail 2 – 10 September 2013
II.4.1.3 HMPC Rapporteurs response to SWP comments	Premail 2 – 10 September 2013
H.4.2 HMPC comments on ethanol report (EMA/281628/2013) within planned revision of the Guideline on excipients in the label and package leaflet of medicinal	
products for human use (CPMP/463/00): for discussion	Postponed to November meeting
II.5 Co-ordination with PDCO	
II.6 Co-ordination with PRAC	
II.7 Co-ordination with PCWP	
II.8 Co-ordination with HCPWP	
II.9 Co-ordination with MIS	
II.10 Co-ordination with COMP	
II.11 Co-ordination with CMDh	
II.12 Co-ordination with Eur. Com.	
III. Organisational matters	
III.1 Organisational Matters Drafting Group	
III.1.1 ORGAM DG (virtual) meeting to be held on 15 October 2013	Report by ORGAM DG Chair
III.1.1.1 Draft agenda (EMA/HMPC/466059/2013): for adoption	Premail 2 – 10 September 2013
III.1.2 Draft ORGAM DG 2014 work programme	Report by ORGAM DG Chair
(EMA/HMPC/544796/2013): for adoption	Premail 2 – 10 September 2013
III.2 Working methodology	
III.2.1 Appointment of new members in MLWP	Report by HMPC Chair/MLWP Chair
III.2.1.1 Procedural aspects for the appointment of new members in the MLWP: for information	

 III.2.1.2 Nominations received from HMPC members with CV: for discussion Nomination of by A. P. Martins and H. Pinto Ferreira dated 31 July 2013 	Premail 1 – 2 September 2013
- Nomination of by N. Grigoras dated 30 August 2013	Premail 1 – 2 September 2013
 Nomination of by Z. Biró-Sándor dated 30 August 2013 	Premail 1 – 2 September 2013
III.2.2 Projects under HMPC work programme for 2012- 2015 (EMA/HMPC/501139/2011)	http://www.ema.europa.eu/docs/en_GB/do cument_library/Work_programme/2011/12 /WC500119957.pdf
III.2.2.1 Forward planning & prioritisation – herbal substances, preparations and combinations for which a monograph should be established in the next years	
- Preparation of a public statement for substances associated with basic safety concerns and not suited to the traditional use system: for discussion	Appointment of Rapporteurs
III.2.3 Discussion on international cooperation in the field of herbal medicines: for discussion	Report by HMPC Chair/HMPC secretariat
III.2.3.1 Draft proposal for HMPC international cooperationKey areas to strengthen the international profile of theEMA in the field of herbal medicine(EMA/HMPC/396677/2013)	To be tabled at meeting
III.2.4 Informal HMPC meeting to be held 10-11 December 2013 in Vilnius, Lithuania: for discussion	Report by A. Kažemekaitis
- Draft agenda	To be tabled at meeting
*III.2.5 Presentation on the restructuring of the Agency organisational: for discussion	Report by
III.2.6 Measures to implement EMA policy on publication of agendas and minutes of scientific committees: for discussion	Report by
III.2.7 List of acronyms used in HMPC minutes	Report by HMPC secretariat
(EMA/HMPC/441838/2013): for discussion	Premail 2 – 10 September 2013
III.2.8 Election of HMPC Chair and Vice-Chair	Report by HMPC secretariat
- Procedure for the election of the HMPC Chair and HMPC Vice-Chair on 11 November (EMA/544790/2013): for adoption	Premail 2 – 10 September 2013
*III.2.9 Information about reflections on the management of declarations of interests and conflicts of interests: for discussion	Report by

III.3 Interaction with interested parties	
III.3.1 Applications for IP to the HMPC: for adoption	Report by HMPC secretariat
III.3.1.1 GP-TCM Research Association dated 12 August	Premail 1 – 2 September 2013
2013	Premail 2 – 10 September 2013
 Interested parties to the HMPC, in particular for the field of non-European Traditional Herbal Medicine 	
(EMA/HMPC/150135/2013)	Premail 1 – 2 September 2013
III.3.1.2 EUCOPE dated 2 August 2013	Premail 1 – 2 September 2013
- Request EUCOPE as Interested Party of HMPC	Premail 1 – 2 September 2013
- International Non Profit Association Articles of Association	Premail 1 – 2 September 2013
- EUCOPE International Non Profit Association By-laws	
IV. Quality	
IV.1 Quality Drafting Group	
Annual meeting of HMPC Q DG/Chairs of Eur. Ph. Expert Gro 13:00 – 16:00 (room 2G) See IV.1.2	oups 13A, 13B & TCM: 17 September 2013,
IV.1.1 Q DG (virtual) meeting held on 25 July 2013	Report by H. Neef
IV.1.1.1 Meeting report (EMA/HMPC/488194/2013): for	Premail 2 – 10 September 2013

IV.1.1.1 Meeting report (EMA/HMPC/488194/2013): for adoption	Premail 2 – 10 September 2013
IV.1.2 Annual meeting HMPC Q DG/Chairs of Eur. Ph.	To be held during the meeting of the MLWP
Expert Groups 13A, 13B & TCM	Tuesday, 17 September 2013
IV.1.2.1 Draft agenda (EMA/HMPC/394564/2013): for	13:00 – 16:00 (room 2G)
adoption	Premail 2 – 10 September 2013
IV.1.3 Draft Q&A on benzene in extracts	Rapporteur: K. Reh
(EMA/HMPC/462947/2013): for adoption	Report by H. Neef
	Postponed to November meeting
IV.1.4 Draft Q DG work programme 2014	Premail 2 – 10 September 2013
(EMA/HMPC/473889/2013): for adoption	
(EMA/HMPC/473889/2013): for adoption	

IV.2 European Pharmacopoeia

Annual meeting of HMPC Q DG/Chairs of Eur. Ph. Expert Groups 13A, 13B & TCM: 17 September 2013, 13:00 – 16:00 (room 2G) See IV.1.2

V. Safety & efficacy

<u>V.1 MLWP</u>

The next meeting of the MLWP will be held 17-19 September 2013

Status on Community herbal monographs, Community list entries, public statements, appointment of new Rapporteurs and Peer-reviewers

See VII.3.2

V.1.1 Overview of status of MLWP assessment work	Report by MLWP Chair
(EMA/HMPC/519580/2007): for discussion	<i>Status July 2013</i> Premail 2 – 10 September 2013
V.1.1.1 Appointment of Rapporteurs	N/A
V.1.1.2 Appointment of Peer-reviewers	N/A
Other relevant topics	
V.1.2 List entry adoption – consistency and transparency in the assessment of available data and options to improve data availability: for discussion	Report by MLWP Chair
V.1.2.1 Draft overview on available genotoxicity data for herbal substances for inclusion into the Community list (EMA/HMPC/283128/2013)	Report by O. Pelkonen/J. Wiesner Premail 1 – 2 September 2013
 Draft evaluation of genotoxicity data for herbal substances including list of questions on possible revision of the assessment approach 	To be tabled at meeting
- Presentation by O. Pelkonen	To be included in the post-meeting mailing
V.1.2.2 Discussion on options to improve the genotoxicity data situation	Report by HMPC secretariat/ L. Anderson
V.1.3 Timelines for revision of monographs due to new scientifically relevant data (validation BSS): for discussion	Report by HMPC Chair/MLWP Chair
 Reflection paper on the reasons and timelines for revision of final Community herbal monographs and Community list entries (EMA/HMPC/326440/2007 Rev.2) 	<u>http://www.ema.europa.eu/docs/en_GB/do cument_library/Other/2009/12/WC5000170 22.pdf</u>
*V.1.4 Draft MLWP 2014 work programme (EMA/HMPC/554850/2013): for adoption	Report by HMPC Chair/MLWP Chair To be tabled at meeting
V.2 Community list entries transmitted to European C	commission

V.3 Community herbal monographs for adoption after systematic review/revision

V.4 Community herbal monographs for adoption (post finalisation)

V.5 Community herbal monographs, Community list entries and public statements for adoption after public consultation

V.5.1 Andrographidis paniculatae folium	Rapporteur: Z. Biró-Sándor; Peer-reviewer: B. Kroes
	No comments received during public consultation
V.5.1.1 Assessment report	Premail 2 – 10 September 2013
V.5.1.1.1 List of references - available references 120/150	Premail 2 – 10 September 2013
V.5.1.2 Public statement	Premail 2 – 10 September 2013

V.6 Community herbal monographs, Community list entries and public statements for adoption for release for public consultation

V.6.1 Rosae flos	Rapporteur: I. Chinou; Peer-reviewer: H. Pinto Ferreira
V.6.1.1 Assessment report	Premail 2 – 10 September 2013
V.6.1.1.1 List of references	Premail 2 – 10 September 2013
V.6.1.2 Monograph	Premail 2 – 10 September 2013

V.7 Community herbal monographs, Community list entries and public statements for discussion

V.8 Reference documents for the preparation of Community herbal monographs, Community list entries, public statements and related documents

V.9 Guidelines

V.9.1 Revision of the guideline on the use of the CTD	Rapporteur: A. Cunney
format in the preparation of a registration application for	Appointment of a Co-Rapporteur and
traditional herbal medicinal products	involvement of ORGAM DG
(EMA/HMPC/71049/2007 Rev. 1): for discussion	Involvement of OKGAM DG
V.9.1.1 Draft concept paper (EMA/HMPC/555178/2013)	Premail 2 – 10 September 2013

VI. Non-clinical assessment/issues

VII. Other relevant business

VII.1 Conferences, presentations & research projects

VII.1.1 Organisation of international symposium on herbal *Report by J. Wiesner*medicines by BfArM to be held on 30 September 2 October 2013 in Bonn, Germany

- Programme

Premail 2 – 10 September 2013

VII.2 International cooperation, collaboration with non-EU regulatory authorities

VII 2.1 LIMPC mosting hold 8.0 July 2012	
VII.3.1 HMPC meeting held 8-9 July 2013	
VII.3.1.1 Table of Decisions (EMA/HMPC/419290/2013)	Premail 1 – 2 September 2013
VII.3.1.2 Meeting report (EMA/HMPC/428663/2013)	Premail 1 – 2 September 2013
VII.3.2 Draft agenda of MLWP meeting to be held 17-19 September 2013 (EMA/HMPC/430303/2013)	Premail 1 – 2 September 2013
VII.3.3 MLWP meeting held 9-11 July 2013	
VII.3.3.1 Table of Conclusions (EMA/HMPC/422555/2013)	Premail 1 – 2 September 2013
VII.3.3.2 Minutes (EMA/HMPC/441130/2013)	Premail 1 – 2 September 2013
VII.3.4 Overview of status of HMPC assessment work – priority list (EMA/HMPC/278067/2006)	Status July 2013 (post-meeting) Premail 2 – 10 September 2013
VII.3.5 Inventory of herbal substances for assessment work – alphabetical order (EMA/HMPC/494079/2007)	Status July 2013 (post-meeting) Premail 2 – 10 September 2013
VII.3.6 Common names of herbal substances in all EU official languages (EMA/HMPC/95087/2011)	<i>Status July 2013</i> Premail 1 – 2 September 2013
VII.3.7 EMA decision P/0156/2013 of 5 July 2013, agreement of a paediatric investigation plan and on the granting of a deferral for dry extract from Betulae cortex (EMA/346350/2013)	http://www.ema.europa.eu/docs/en_GB/do cument_library/PIP_decision/WC50014762 .pdf
*VII.3.8 EMA decision P/0184/2013 of 31 July 2013 on a product specific waiver for capsici acris extractum spissum normatum (EMA/418994/2013)	http://www.ema.europa.eu/docs/en_GB/do cument_library/PIP_decision/WC50014852 .pdf
VII.3.9 Meeting report of the MLWP-AESGP hearing held on 14 May 2013 (EMA/HMPC/413550/2013)	http://www.ema.europa.eu/docs/en_GB/do cument_library/Report/2013/07/WC500140 577.pdf
VII.3.10 Assessment report summaries for the public (ARSP) from July 2013	
- Walnut Leaf - summary for the public (EMA/432131/2013)	To be tabled at meeting
- Dittany of Crete herb - summary for the public (EMA/441263/2013)	To be tabled at meeting
- White horehound - summary for the public (EMA/446032/2013)	To be tabled at meeting
VII.3.11 Assessment report summaries for the public (ARSP)	After translation by CdT followed by review by HMPC members from 23 August to 13 September
- Psyllium seed – summary for the public (EMA/322933/2013)	Premail 2 – 10 September 2013

Premail 2 – 10 September 2013 Premail 2 – 10 September 2013
Premail 2 – 10 September 2013
Premail 2 – 10 September 2013
To be included in the post-meeting mailing
To be included in the post-meeting mailing
To be included in the post-meeting mailing
Premail 2 – 10 September 2013
Premail 2 – 10 September 2013
-